This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Introgen Therapeutics, Inc.
Drug Names(s): MDA-7
Description: INGN 241 is a modified adenoviral vector that carries the cancer cell killing mda-7 gene. The mda-7 gene encodes the antitumor cytokine, interleukin 24 (IL-24), the protein responsible for INGN241's broad therapeutic properties.
Deal Structure: Introgen entered into a research and license agreement with Corixa Corporation pursuant to which Introgen acquired an exclusive, worldwide license to the mda-7 gene for gene therapy applications. The agreement is effective until the expiration of the subject patents. It is terminable upon the breach or insolvency of either party, or upon Introgen notice on a patent-by-patent or product-by-product basis. Under the agreement, Introgen paid Corixa an initial license fee and have agreed to make additional payments upon the achievement of development milestones, as well as royalty payments on product sales. Introgen also made research payments to Corixa in connection with research it performed involving the mda-7 gene.
In April 2005, GlaxoSmithKline announced the acquisition of Corixa Corporation. The acquisition was structured as a cash for stock transaction, and the shareholders of Corixa received $4.40 per common share, representing a total value of approximately $300 million.
Partners: GlaxoSmithKline plc
INGN 241 News
Additional information available to subscribers only: